on Immunic AG
Immunic, Inc. Set to Participate in December Investor Conference
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm focused on small molecule therapies for chronic inflammatory and autoimmune diseases, announced participation in the Piper Sandler 36th Annual Healthcare Conference. The event will be held from December 3-5, 2024, in New York. CEO Daniel Vitt, Ph.D., will engage in a fireside chat on December 5, while CFO Glenn Whaley and VP Jessica Breu will also hold one-on-one investor meetings.
The discussion and meetings aim to present the company's progress, including advancements in treatments for multiple sclerosis and ulcerative colitis. Vidofludimus calcium, their leading candidate, is undergoing phase 3 and 2 trials, showcasing neuroprotective and anti-inflammatory benefits.
Interested parties can access the event webcast on Immunic's website, with a replay available for 90 days post-conference.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Immunic AG news